Penile cancer is a disease in which cancerous cells forms into tissues of the penis, a male sex organ which helps body to pass sperms and excrete urine from body. Penile cancers is generally caused by body fluid that gets entangled into the skin. If these body fluids are not washed off on regular basis, it may produce cancer-causing effects. Acquired immune deficiency syndrome (AIDS) and human papilloma virus (HPV) are the most common viruses that cause penile cancer. Other causes include frequent tobacco use, poor hygiene, and other skin diseases. Smokers and older men are more prone to suffer from penile cancer. Signs and symptoms of penile cancer include bleeding, lumps, redness, sores among others. According to United Nations Programme on HIV/AIDS (UNAIDS), 15.5 Mn patients are on antiretroviral therapy (as of June 2015), 36.9 Mn people globally were living with HIV (as of December 2014), 2 Mn patients became newly infected with HIV (as of December 2014), and 1.2 Mn people died from AIDS-related illness (as of December 2014). This has encouraged pharmaceutical companies to invest in penile cancer treatment market and develop drugs for penile cancer.

Penile Cancer Treatment Market: Drivers and Restraints

Increasing incidence of penile cancer is a major driver for the growth of global penile cancer treatment market. Advancement in technology coupled with personalized medicine, and cost effective treatment procedures for penile cancer will drive penile cancer market across the globe. However, lack of inadequate reimbursement policies, healthcare literacy, and commercially less availability of drugs for the treatment of penile cancer are the factors which will hamper the growth of global penile cancer treatment market over the forecasted period.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1462